There are 594 resources available
AI in radiation treatment planning
Presenter: Joseph Deasy
Session: The role of AI in lung cancer
Resources:
Slides
Webcast
What matters to patients with oligometastatic disease
Presenter: Jill Feldman
Session: Advances in oligometastatic disease
Resources:
Slides
Webcast
Q&A and discussion
Session: The role of AI in lung cancer
Resources:
Webcast
Q&A and discussion
Session: Advances in oligometastatic disease
Resources:
Webcast
Introduction and first vote
Presenter: Heather Wakelee
Session: Duration of adjuvant treatment: Is “as long as possible” the key?
Resources:
Slides
Webcast
PRO: As long as possible
Presenter: Hye Ryun Kim
Session: Duration of adjuvant treatment: Is “as long as possible” the key?
Resources:
Slides
Webcast
CONTRA: Limited duration
Presenter: Rafal Dziadziuszko
Session: Duration of adjuvant treatment: Is “as long as possible” the key?
Resources:
Slides
Webcast
Second vote and conclusions/discussion
Presenter: Heather Wakelee
Session: Duration of adjuvant treatment: Is “as long as possible” the key?
Resources:
Slides
Webcast
Case presentation and the medical oncologist perspective
Presenter: JUNKO TANIZAKI
Session: How to manage locally advanced NSCLC with poor lung function
Resources:
Slides
Webcast
5MO - First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) and PD-L1 =50% from the phase II portion of KRYSTAL-7
Presenter: Marina Garassino
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast